Travere Therapeutics (TVTX) Total Liabilities (2011 - 2026)

Travere Therapeutics' Total Liabilities history runs 16 years deep, the most recent figure standing at $456.5 million for Q1 2026.

• Quarterly Total Liabilities fell 11.53% year-over-year to $456.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.5 million (down 11.53% YoY) and the FY2025 annual result came in at $490.4 million, down 8.35% from the prior year.
• Total Liabilities was $456.5 million for Q1 2026 at Travere Therapeutics, down from $490.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $629.7 million in Q4 2022 and bottomed at $456.5 million in Q1 2026.
• A 5-year average of $560.3 million and a median of $553.1 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 54.54% — and 2024, when it slipped 13.54%.
• Travere Therapeutics' Total Liabilities stood at $629.7 million in 2022, then dropped by 6.61% to $588.1 million in 2023, then fell by 9.02% to $535.0 million in 2024, then dropped by 8.35% to $490.4 million in 2025, then slipped by 6.91% to $456.5 million in 2026.
• Business Quant data shows TVTX's Total Liabilities at $456.5 million in Q1 2026, $490.4 million in Q4 2025, and $465.0 million in Q3 2025.